Innervate Radiopharmaceuticals Llc (formerly: Illumina Radiopharmaceuticals Llc)

This phase 2 study tests a new radioactive imaging agent, 18F-mFBG, to measure nerve damage in the hearts of 20 people with stable heart failure and implantable defibrillators (ICDs). The goal is to see if the agent can reveal differences in nerve function between those who have …

This study tests a new radioactive tracer called 18F-mFBG to see if it can detect nerve damage in the heart caused by Lewy body diseases like Parkinson's and Lewy body dementia. About 20 adults will get a PET scan after an injection of the tracer. The goal is to see if the scan c…